On 2 June 2026, China's National Medical Products Administration (NMPA) released a draft proposal for public consultation that would grant priority review status to certain active pharmaceutical ingredients (APIs). The draft proposal outlines three circumstances under which an API may qualify for priority review: APIs used in urgently needed medicines included on China's drug shortage lists, or otherwise deemed critical to public health. The first domestic registration of an

In the ever-evolving world of healthcare, having reliable access to high-quality reference medicines is essential for research, development, and patient care. MAAB Group, a pioneer in healthcare solutions, introduces its Reference Medicine Sourcing Service, designed to meet the diverse needs of medical professionals and institutions. What is MAAB Group's Reference Medicine Sourcing Service? MAAB Group's Reference Medicine Sourcing Service provides a comprehensive solution for